Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer

 
• By Joseph Haas

Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.

Genetech
Genentech's inavolisib may offer a new treatment option in HR+/HER2- breast cancer • Source: Shutterstock: Michael Vi

More from Clinical Trials

More from R&D